| __timestamp | ImmunityBio, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 13774000 |
| Thursday, January 1, 2015 | 226206000 | 22479000 |
| Friday, January 1, 2016 | 94391000 | 27388000 |
| Sunday, January 1, 2017 | 53821000 | 35610000 |
| Monday, January 1, 2018 | 35463000 | 49007000 |
| Tuesday, January 1, 2019 | 46456000 | 61139000 |
| Wednesday, January 1, 2020 | 71318000 | 68836000 |
| Friday, January 1, 2021 | 135256000 | 97592000 |
| Saturday, January 1, 2022 | 102708000 | 106903000 |
| Sunday, January 1, 2023 | 129620000 | 120998000 |
In pursuit of knowledge
In the dynamic world of biotechnology, managing operational costs is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and ImmunityBio, Inc. over the past decade, from 2014 to 2023.
ImmunityBio, Inc. has seen a significant increase in SG&A expenses, peaking in 2015 with a staggering 2,262% rise compared to 2014. This trend reflects their aggressive expansion and investment in research and development. Meanwhile, Vericel Corporation has maintained a more consistent growth in expenses, with a notable 780% increase from 2014 to 2023, indicating a steady scaling of operations.
Understanding these financial strategies provides insights into how these companies balance innovation with operational efficiency, offering a glimpse into their future trajectories in the competitive biotech landscape.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.